Interleukin Genetics Inc. slipped further toward a de-listing from the New York Stock Exchange’s Amex board after the exchange rejected its plan to regain compliance.

The Waltham genetic biomarker maker originally fell from the exchange’s graces two days before Christmas last year, when its stockholders equity dropped below the $6 million threshold required by the NYSE and it posted five consecutive quarters of net and operating losses.

Interleukin said it appealed the decision and requested a hearing before the exchange’s listing qualifications panel to plead its case, which it expects to be slated with 45 days.